Vidhya Sabapathy, MD
Infectious Disease · Suwanee, GANPI 1588058879
Payments from drug & device makers
Across 184 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$614
- Paratek Pharmaceuticals, Inc.$571
- Merck$508
- Insmed, Inc.$404
- Gilead$401
- AbbVie$347
- plus $805 from 15 others
What the payments were for
- Food & beverage$3,47895%
- Education$1725%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 33 | $614 |
| Paratek Pharmaceuticals, Inc. | 38 | $571 |
| Merck | 22 | $508 |
| Insmed, Inc. | 18 | $404 |
| Gilead | 18 | $401 |
| AbbVie(2 entities) | 18 | $347 |
| Melinta Therapeutics, LLC | 9 | $166 |
| Astellas Pharma US Inc | 2 | $99 |
| Pfizer | 4 | $97 |
| Napo Pharmaceuticals Inc | 4 | $96 |
| Shionogi Inc | 4 | $66 |
| La Jolla Pharmaceutical Company | 3 | $65 |
| Mayne Pharma Commercial LLC | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $26 |
| Cumberland Pharmaceuticals, Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Surgenex LLC | 1 | $24 |
| Organogenesis Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,650 in reported general payments places this provider in the 60th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 35 | $27,796 |
| Fosfomycin Tromethamine | 12 | $2,895 |
| Doxycycline Hyclate | 42 | $1,951 |
| Meropenem | 14 | $1,659 |
| CeftriaxoneCeftriaxone Sodium | 41 | $1,283 |
| Fluconazole | 17 | $702 |
| Linezolid | 12 | $582 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $346 |
| CefuroximeCefuroxime Axetil | 15 | $306 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $206 |
| Amoxicillin | 36 | $175 |
| Ciprofloxacin Hcl | 18 | $155 |
| Levofloxacin | 22 | $105 |
| Cephalexin | 27 | $85 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Suwanee
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.